A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers.

Brixen K, Nielsen HK, Mosekilde L, Flyvbjerg A

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1 Jun 1990Cited by 99 (Europe PMC)

PMID2382586DOI10.1002/jbmr.5650050610PepBankPUB-02382586

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
In healthy men, rhGH increased serum somatomedin C during treatment (p less than 0.001).
In plain wordsIn healthy men, rhGH increased serum somatomedin C from baseline during treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum somatomedin C during treatment
Study
n: not reported in source
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Serum somatomedin C rose during treatment (p less than 0.001) but was not significantly different from baseline at day 14.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258601
02HumanNon-randomized trialEfficacy outcome
In healthy men, serum somatomedin C did not significantly differ from baseline at day 14 after rhGH treatment.
In plain wordsIn healthy men, serum somatomedin C did not significantly differ from baseline at day 14 after rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeSerum somatomedin C at day 14
Study
n: not reported in source
Comparator
Baseline
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Serum somatomedin C rose during treatment (p less than 0.001) but was not significantly different from baseline at day 14.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258602
03HumanNon-randomized trialEfficacy outcome
In healthy men, rhGH increased urinary hydroxyproline/creatinine (p less than 0.001), which remained elevated for 4 weeks.
In plain wordsIn healthy men, rhGH increased urinary hydroxyproline/creatinine from baseline, with elevation lasting 4 weeks.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary hydroxyproline/creatinine
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
The fasting urinary hydroxyproline/creatinine (p less than 0.001) and calcium/creatinine ratios (p less than 0.01) increased during treatment and remained elevated for 4 and 2 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258603
04HumanNon-randomized trialEfficacy outcome
In healthy men, rhGH increased urinary calcium/creatinine (p less than 0.01), which remained elevated for 2 weeks.
In plain wordsIn healthy men, rhGH increased urinary calcium/creatinine from baseline, with elevation lasting 2 weeks.
Peptide
HGH (somatotropin)
Outcome
IncreaseUrinary calcium/creatinine
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
The fasting urinary hydroxyproline/creatinine (p less than 0.001) and calcium/creatinine ratios (p less than 0.01) increased during treatment and remained elevated for 4 and 2 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258604
05HumanNon-randomized trialEfficacy outcome
In healthy men, rhGH increased serum BGP during treatment (p less than 0.001), with elevation for 6 months (p less than 0.02).
In plain wordsIn healthy men, rhGH increased serum BGP from baseline, with elevation lasting 6 months.
Peptide
HGH (somatotropin)
Outcome
IncreaseSerum BGP
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Serum bone gamma-carboxyglutamic acid-containing protein (BGP) increased during treatment (p less than 0.001) and remained elevated for 6 months (p less than 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258605
06HumanNon-randomized trialEfficacy outcome
In healthy men, serum bone alkaline phosphatase initially fell during rhGH treatment (p less than 0.001).
In plain wordsIn healthy men, serum bone alkaline phosphatase initially fell from baseline during rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseBone alkaline phosphatase during treatment
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Serum bone alkaline phosphatase (B-AP), after an initial fall in the treatment period (p less than 0.001), increased slightly in the following months (p less than 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258606
07HumanNon-randomized trialEfficacy outcome
In healthy men, serum bone alkaline phosphatase increased slightly in the months following rhGH treatment (p less than 0.01).
In plain wordsIn healthy men, serum bone alkaline phosphatase increased slightly in the months after rhGH treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone alkaline phosphatase following treatment
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
Serum bone alkaline phosphatase (B-AP), after an initial fall in the treatment period (p less than 0.001), increased slightly in the following months (p less than 0.01).
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258607
08HumanNon-randomized trialEfficacy outcome
In healthy men receiving rhGH, bone mineral content exceeded the prestudy value at day 14 (p less than 0.05).
In plain wordsIn healthy men receiving rhGH, bone mineral content exceeded baseline at day 14.
Peptide
HGH (somatotropin)
Outcome
IncreaseBone mineral content at day 14
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
In the rhGH group BMC was significantly higher than the prestudy value at day 14 (p less than 0.05) but was unaltered at the end of study.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258608
09HumanNon-randomized trialEfficacy outcome
In healthy men receiving rhGH, bone mineral content was unaltered at study end.
In plain wordsIn healthy men receiving rhGH, bone mineral content did not change from baseline at study end.
Peptide
HGH (somatotropin)
Outcome
No significant changeBone mineral content at study end
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
0.1 IU/kg twice a day · subcutaneous · 7 daysAs given in this study (human).
Source sentences
Summary
In the rhGH group BMC was significantly higher than the prestudy value at day 14 (p less than 0.05) but was unaltered at the end of study.
1 context sentence(design, population, supporting numbers)
Summary · context
The effects of recombinant human growth hormone (rhGH) on biochemical markers of bone turnover and bone mineral content (BMC) were investigated in 20 normal male volunteers (aged 22-31 years) randomized to treatment for 7 days with either rhGH (0.1 IU/kg subcutaneously twice a day) or placebo.
Report a problemFND-0238258609

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.